In short
This article discusses clinical trials investigating the use of Artemisia Vulgaris (312), commonly known as mugwort, in allergy testing. These studies aim to assess the effectiveness and safety of sublingual immunotherapy for patients with various pollen allergies, including birch and grass pollen. While Artemisia Vulgaris is not the primary focus of these trials, it is used as a comparative allergen in skin prick tests to evaluate patients' sensitivities.
At a glance
- Drug Name
- Artemisia Vulgaris (312)
- Common Name
- Mugwort
- Use in Trials
- Comparative allergen in skin prick tests
- Product Form
- Solution for skin-prick test
- Main Trial Objectives
- Assess efficacy and safety of sublingual immunotherapy for birch and grass pollen allergies
- Target Conditions
- Moderate to severe allergic rhinitis/rhinoconjunctivitis due to specific pollens
- Key Inclusion Criteria
- Adults 18-65, specific allergy history, positive skin prick test, elevated specific IgE levels
- Primary Endpoint
- Differences in Combined Symptom and Medication Score (CSMS) during peak pollen periods
What is ARTEMISIA VULGARIS (312)?
ARTEMISIA VULGARIS (312), also known as 312 Mugwort, is an allergen extract used in diagnostic tests for allergic diseases. It is derived from the mugwort plant, which is a common cause of allergies in some individuals. This substance is classified as a structurally diverse substance - allergen, meaning it contains various components that can trigger allergic reactions in sensitive people.
Medical Uses
The primary use of ARTEMISIA VULGARIS (312) is in diagnostic tests for allergic diseases, specifically in skin prick tests. These tests are used to identify allergies in patients who may be experiencing symptoms such as: Allergic rhinitis (hay fever) Allergic conjunctivitis (eye allergy) Asthma related to mugwort allergy By using this allergen extract in a controlled medical setting, healthcare providers can determine if a patient is allergic to mugwort and develop appropriate treatment plans.
Administration
ARTEMISIA VULGARIS (312) is administered as a solution for skin-prick test. The typical administration is as follows: Route: Topical (applied to the skin) Dose: Usually 1 drop Frequency: Typically a one-time application during the allergy test It's important to note that this substance should only be administered by trained healthcare professionals in a controlled medical environment.
Clinical Trials
While the provided clinical trial information doesn't directly involve ARTEMISIA VULGARIS (312) as the main study drug, it is mentioned as an auxiliary product in trials related to other allergens. These trials focus on: Assessing the efficacy and safety of sublingual immunotherapy for birch pollen allergy Evaluating sublingual immunotherapy for grass pollen allergy The inclusion of ARTEMISIA VULGARIS (312) in these trials suggests its importance in comprehensive allergy testing and diagnosis, even when studying other specific allergens.
Potential Side Effects
As ARTEMISIA VULGARIS (312) is used in diagnostic testing, the potential for side effects is generally low when used as directed. However, patients should be aware of the following possible reactions: Local skin irritation at the test site Itching or redness In rare cases, a more severe allergic reaction It's crucial to inform your healthcare provider of any unusual reactions during or after the skin prick test.
Precautions
Before undergoing a skin prick test with ARTEMISIA VULGARIS (312), patients should: Inform their doctor of all current medications, especially antihistamines or other allergy medications Disclose any history of severe allergic reactions Mention any skin conditions that might affect the test results Follow all pre-test instructions provided by the healthcare team Patients with a history of anaphylaxis or severe allergic reactions should be tested with extra caution and only under close medical supervision.